PDCD1 and melanoma: Notably, recent clinical trial results showed that combining relatlimab with nivolumab (anti-PD-1 mAb) provides a satisfying benefit for patients with unresectable melanoma or patients with resectable melanoma as neoadjuvant therapy46,61.